All In Biotech

Drug Trial Radar · NCT01082874

PeriOperative ISchemic Evaluation-2 Trial

A Large, International, Placebo-controlled, Factorial Trial to Assess the Impact of Clonidine and Acetyl-salicylic Acid (ASA) in Patients Undergoing Noncardiac Surgery Who Are at Risk of a Perioperative Cardiovascular Event

Last checked: Nov 19, 2026Latest source record: Aug 25, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 10,010 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

10,010

Actual

Start

Jul 2010

Primary completion

Mar 2014

Study completion Jan 2015

Sponsor

Lead sponsor
Hamilton Health Sciences CorporationAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
McMaster University
First posted
Mar 9, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Factorial
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, from 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Major surgeries not involving the heart are common, and major heart problems during or after such surgeries represent a large population health problem. Few treatments to prevent heart problems around the time of surgery have been tested. There is encouraging data suggesting that small doses of Acetyl-Salicylic Acid (ASA) and Clonidine, which are two medications, given individually for a short period before and after major surgeries may prevent major heart problems. The POISE-2 Trial is a large international study to test if ASA and Clonidine can prevent heart attacks and deaths from heart problems around the time of surgery.

Conditions

  • Cardiovascular Disease

Interventions

  • Active ClonidineDrug

    Pre-op (goal 2-4 hours): 2 x 0.1mg oral tablets and transdermal patch (0.2 mg/day). Patch to be removed 72 hours post-op.

  • Placebo ClonidineDrug

    Pre-op (goal 2-4 hours): 2 oral placebo tablets and transdermal placebo patch. Patch to be removed 72 hours post-op.

  • Active ASADrug

    Pre-op (goal 2-4 hours): 2 x 100mg oral tablets. Post-op: patients ingest one tablet a day (100 mg ASA) for 7 days if patient was were taking ASA chronically prior to surgery or for 30 days if they were not chronically taking ASA prior to surgery

  • Placebo ASADrug

    Pre-op (goal 2-4 hours): 2 oral placebo tablets. Post-op: patients ingest one placebo tablet a day for 7 days if patient was were taking ASA chronically prior to surgery or for 30 days if they were not chronically taking ASA prior to surgery

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Composite of All-cause Mortality and Nonfatal MITime frame: 30 days
  2. All-cause Mortality and Nonfatal MITime frame: 1 year

Locations

23 sites in 23 countries. Site status is shown where the registry gives one.

  • National Coordination Office

    Cleveland, Ohio

  • National Coordination Office

    Rosario, Argentina

  • National Coordination Office Australia and New Zealand

    Parkville, Victoria, Australia

  • National Coordination Office

    Vienna, Austria

  • National Coordination Office

    Brussels, Belgium

  • National Coordination Office

    São Paulo, Brazil

  • National Coordination Office

    Hamilton, Ontario, Canada

  • National Coordination Office

    Santiago, Chile

  • National Coordination Office

    Bucamaranga, Colombia

  • National Coordination Office

    Herlev, Denmark

  • National Coordination Office

    Boulogne-Billancourt, France

  • National Coordination Office

    Bonn, Germany

  • National Coordination Office

    Hong Kong, Hong Kong

  • National Coordination Office

    Bangalore, India

  • National Coordination Office

    Milan, Italy

  • National Coordination Office

    Kuala Lumpur, Malaysia

  • National Coordination Office

    Auckland, New Zealand

  • National Coordination Office

    Islamabad, Pakistan

  • National Coordination Office

    Lima, Peru

  • National Coordination Office

    Durban, South Africa

  • National Coordination Office

    Barcelona, Spain

  • National Coordination Office

    Basel, Switzerland

  • National Coordination Office

    Hull, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.